NASDAQ:FBLG FibroBiologics (FBLG) Stock Price, News & Analysis $1.14 -0.09 (-6.97%) Closing price 04:00 PM EasternExtended Trading$1.15 +0.02 (+1.67%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About FibroBiologics Stock (NASDAQ:FBLG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FibroBiologics alerts:Sign Up Key Stats Today's Range$1.08▼$1.2750-Day Range$0.81▼$1.3852-Week Range$0.76▼$13.59Volume162,250 shsAverage Volume290,629 shsMarket Capitalization$42.83 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company OverviewFibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Read More… FibroBiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreFBLG MarketRank™: FibroBiologics scored higher than 58% of companies evaluated by MarketBeat, and ranked 724th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingFibroBiologics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFibroBiologics has only been the subject of 2 research reports in the past 90 days.Read more about FibroBiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for FibroBiologics are expected to grow in the coming year, from ($0.53) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroBiologics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroBiologics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFibroBiologics has a P/B Ratio of 28.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about FibroBiologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.23% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in FibroBiologics has recently decreased by 32.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroBiologics does not currently pay a dividend.Dividend GrowthFibroBiologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.23% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in FibroBiologics has recently decreased by 32.00%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.43 News SentimentFibroBiologics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for FibroBiologics this week, compared to 1 article on an average week.MarketBeat Follows8 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, FibroBiologics insiders have not sold or bought any company stock.Percentage Held by Insiders20.80% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about FibroBiologics' insider trading history. Receive FBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address FBLG Stock News HeadlinesFibroBiologics to Present at The Cell & Gene Meeting on the MediterraneanApril 11, 2025 | globenewswire.comOTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCRApril 9, 2025 | msn.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.April 28, 2025 | Altimetry (Ad)FibroBiologics announces opening of new lab facilityApril 9, 2025 | markets.businessinsider.comFibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based TherapeuticsApril 8, 2025 | globenewswire.comFibroBiologics Reports 2024 Financial Results and UpdatesApril 4, 2025 | tipranks.comFBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25…April 3, 2025 | finance.yahoo.comFibroBiologics announces advancement in results of brain tissue repairApril 3, 2025 | markets.businessinsider.comSee More Headlines FBLG Stock Analysis - Frequently Asked Questions How have FBLG shares performed this year? FibroBiologics' stock was trading at $2.00 at the beginning of 2025. Since then, FBLG shares have decreased by 43.3% and is now trading at $1.1350. View the best growth stocks for 2025 here. How were FibroBiologics' earnings last quarter? FibroBiologics, Inc. (NASDAQ:FBLG) released its quarterly earnings data on Monday, March, 31st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. When did FibroBiologics IPO? FibroBiologics (FBLG) raised $144 million in an IPO on Wednesday, January 31st 2024. The company issued 4,806,226 shares at a price of $30.00 per share. How do I buy shares of FibroBiologics? Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of FibroBiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings3/31/2025Today4/28/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBLG Previous SymbolNASDAQ:FBLG CIK1958777 Webwww.fibrobiologics.com Phone281-671-5150FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,045.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,490,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-225.34% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book28.38Miscellaneous Outstanding Shares37,735,000Free Float28,835,000Market Cap$42.83 million OptionableN/A Beta0.16 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:FBLG) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.